In the third part of this video series, Susan Cantrell, CEO of AMCP, discusses the impact of drug prices on patient adherence with Managed Healthcare Executive.
In the third part of this video series, Susan Cantrell, CEO of AMCP, discusses the impact of drug prices on patient adherence.
While cost-sharing can be expressed as a well-intended benefit design, studies show it can negatively affect long-term adherence, Cantrell shared. AMCP supports efforts to reduce out-of-pocket costs, however when it comes to premiums and long-term consequences, there could be consequences.
She also highlighted the Inflation Reduction Act (IRA), expressing concerns about potential unintended consequences, such as manufacturers adjusting launch prices.
AMCP historically opposes government intervention in pricing, as it’s important to monitor any cost-shifting changes. Cantrell added AMCP actively works with others, sharing thoughts and helpful materials about how policies are put into action.
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Jack Linehan of Epstein Becker Green Discusses Drug Coupons, Accumulators
July 9th 2020In this week's episode of Tuning Into The C-Suite podcast, Senior Editor Peter Wehrwein has a conversation with John "Jack" Linehan, a lawyer for Epstein Becker Green, about coupons and accumulators. Jack is an expert on drug distribution and reimbursement, and few people know as much about coupons and accumulators as he does. Peter and Jack go over some of the basics, who is advantaged and disadvantaged, and then dive into some the details on CMS regulations and how recent proposed changes to Medicaid best price rules would, if finalized, affect coupons and accumulators.
Listen
HHS Needs More Rebate Information To Negotiate Medicare Drug Prices, Say USC Experts
February 19th 2024The Health and Human Services department could wind up overpaying (or possibly underpaying) for the drugs for which it is negotiating a “maximum fair price” for Medicare under the Inflation Reduction Act, argue experts at the USC Schaeffer Center for Health Policy and Economics. A fuller picture of rebates and net prices could help that from happening, they say.
Read More
ICER Updates its Assessment Framework to Include New Measures of Value
September 25th 2023ICER adds a more formal process to evaluate the diversity of clinical trials and an assessment of a product’s impact on patient and caregiver productivity. ICER also plans to evaluate how newer methods — which would consider the change of a drug’s price over time and disease severity — can be applied to its value assessment.
Read More